Search

Harmony Biosciences Holdings Inc

Lezárt

SzektorEgészségügy

38.13 0.55

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

37.86

Maximum

38.28

Fő mutatók

By Trading Economics

Bevétel

43M

75M

Értékesítés

46M

261M

P/E

Szektor átlag

12.343

57.371

Egy részvényre jutó nyereség

1.28

Profit margin

28.87

Munkavállalók

293

EBITDA

53M

102M

Ajánlások

By TipRanks

Ajánlások

Semleges

12 hónapos előrejelzés

+9.12% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 3.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

160M

2.2B

Előző nyitás

37.58

Előző zárás

38.13

Hangulat hírek alapján

By Acuity

50%

50%

150 / 340 Rangsor szerint Healthcare

Harmony Biosciences Holdings Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 21. 22:31 UTC

Harmony Biosciences Holdings Inc. is trading higher in after-market hours, reaching the upper end of its one-month range and above the 20-day moving average.

2026. aug. 20. 23:31 UTC

Harmony Biosciences Holdings Inc shares are higher in after-market trading, supported by strong momentum above the 20-day moving average and within its one-month range.

2026. aug. 19. 19:56 UTC

Harmony Biosciences Holdings Inc. is trading higher, reaching a session high and remaining above its 20-day moving average during Wednesday's session.

2026. aug. 14. 19:46 UTC

Harmony Biosciences shares are lower as the Pharmaceuticals sub-sector declines. The stock remains above its 20-day moving average, indicating some underlying strength.

2026. aug. 13. 22:51 UTC

Harmony Biosciences shares are rising in after-market trading, supported by favorable macroeconomic indicators and a broader trend in major averages closing higher.

2026. aug. 11. 19:21 UTC

Harmony Biosciences Holdings Inc. is trading higher today, continuing its upward trajectory since Monday's close amid broader market trends and rising oil prices.

2026. aug. 10. 19:46 UTC

Harmony Biosciences Holdings Inc is trading higher, continuing its upward trend since Friday. The stock remains above its 20-day moving average.

2026. aug. 7. 20:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower amid broader market declines and decreasing Treasury yields following recent economic data.

2026. aug. 6. 23:51 UTC

Harmony Biosciences Holdings Inc shares declined during after-market hours, struggling to maintain earlier gains amid a lack of specific news to explain the movement.

2026. aug. 5. 20:03 UTC

Social Media
Event
News

Harmony Biosciences shares are lower despite new Phase 1 data on BP-205. Truist maintains a Hold rating and raises the price target to $34.

2026. aug. 4. 20:04 UTC

Social Media
News
Event

Harmony Biosciences reported strong Q2 earnings of $75.43 million and reaffirmed 2026 revenue guidance, with shares trading sharply higher during the session.

2026. aug. 3. 23:11 UTC

Harmony Biosciences shares are higher in after-hours trading, supported by positive sentiment from the Institute for Supply Management's manufacturing PMI report.

2026. aug. 1. 00:01 UTC

Shares of Harmony Biosciences Holdings Inc are higher in after-market trading, reflecting notable strength since Friday's close without any specific news driving the move.

2026. júl. 31. 23:21 UTC

Harmony Biosciences Holdings Inc. is trading higher during after-market hours, reflecting steady price increases since Friday's close, despite no specific news identified.

2026. júl. 28. 18:26 UTC

News

Shares of Harmony Biosciences are lower despite a 30% revenue increase for WAKIX, as market sentiment reflects concerns over potential cash flow erosion.

2026. júl. 27. 19:41 UTC

Shares of Harmony Biosciences Holdings Inc. are higher today, breaking from a recent upward trend despite the absence of specific company news.

2026. júl. 24. 17:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower today, continuing a decline since Thursday's close, despite earlier reaching a session high.

2026. júl. 22. 20:01 UTC

News

Harmony Biosciences Holdings Inc is trading lower despite preliminary Q2 2026 results showing record net product revenue of approximately $261 million, a 30% year-over-year increase.

2026. júl. 21. 21:01 UTC

Harmony Biosciences Holdings Inc. shares are lower in after-market trading, diverging from a broader market rebound despite no specific news driving the decline.

Társak összehasonlítása

Árváltozás

Harmony Biosciences Holdings Inc Előrejelzés

Célár

By TipRanks

9.12% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 41.63 USD  9.12%

Magas 55 USD

Alacsony 30 USD

8 Wall Street elemző 12 hónapos célárain alapulva a(z)Harmony Biosciences Holdings Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Semleges

8 ratings

3

Vétel

4

Tartás

1

Eladás

Hangulat

By Acuity

150 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Neutral

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
help-icon Live chat